Yann Foricher

Head of Small Molecules Medicinal Chemistry Sanofi

Seminars

Thursday 12th November 2026
Panel Discussion: Target-Focused vs High-Throughput Approaches for Discovering Therapeutically Effective RNA-Targeting Small Molecules
9:00 am
  • What are the advantages and challenges associated with target-focused approaches?
  • What are the advantages and challenges associated with high-throughput phenotypic or cell-based functional screening approaches?
  • How is phenotypic RNA modulation connected back to a specific RNA target, binding site, or mechanism of action?
  • How does each approach manage generating actionable SAR and program attrition?
Thursday 12th November 2026
Panel Discussion: Establishing RNA-Targeted Small Molecules as a Generalizable Drug Modality
3:00 pm
  • Which disease areas beyond rare genetic indications – respiratory, immunology, and other high-prevalence settings – are genuinely within reach, and what makes a target there tractable?
  • What new chemotypes, mechanisms, and platforms are needed to expand beyond risdiplam- and branaplam-like analogs and a handful of target classes – and how far should we extend the one validated mechanism class versus seek genuinely new ones?
  • What translational, safety, and selectivity evidence is required to convince the field that RNA targeting is a generalizable modality rather than a niche?
Yann Foricher Sanofi Head Small Molecules Medicinal Chemistry biotech leader